Navigation Links
Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
Date:1/31/2013

SAN FRANCISCO, Jan. 31, 2013 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced the expansion of its senior management team with the appointment of Edward C. Albini as chief financial officer. Mr. Albini has more than 25 years of life science industry experience, including more than 14 years in various financial management positions at Genentech.

"Ed joins Sutro at a very exciting time as we continue to advance our own pipeline and to collaborate with pharmaceutical and biotech companies utilizing our novel, cell-free approach for the design, development and manufacturing of next-generation antibody drug conjugates (ADCs) and bispecific antibodies," said William Newell , chief executive officer of Sutro Biopharma. "He brings a tremendous skill set and depth of experience that will provide us with important insight and direction at this important stage for our company."

Mr. Albini joins Sutro from Itero Biopharmaceuticals, a company focusing on the development and commercialization of protein therapeutics, where he was chief financial officer. Prior to joining Itero, he was chief financial officer at Novacea, where he was responsible for oversight and management of all financial activities, including debt and equity financings, strategic financial evaluation, financial planning and investor relations. Earlier, Mr. Albini was the chief financial officer of Lynx Therapeutics, where he led equity and debt offerings and negotiated revenue-bearing agreements for the company. He worked for more than 14 years in various financial management positions at Genentech, including director of finance for international operations and director of financial planning and analysis. Mr. Albini holds a master's in business administration from the Unive
'/>"/>

SOURCE Sutro Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sutro Announces Newly Formed Scientific Advisory Board
2. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
3. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
4. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
5. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors ... Plague.” In this time period, doctors did not know that ... to the death of vulnerable patients. In the same way, ... may be unwittingly transmitting herpes viruses to their patients. The ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Recruiters Need to Achieve Their ... Trial Site Recruitment Goals, ... Science,Inc., a leading source of healthcare provider data and analytics ... Investigators,their latest innovation for clinical site recruitment. Clinical,Investigators dramatically reduces ...
... Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI), today announced ... Board has changed from "LRRI.OB" to "ARNI.OB",effective July ... Therapeutics, Inc. is a clinical-stage biopharmaceutical company,that develops ... patients. Arno,s lead compound is AR-67, a novel, ...
... Outsourcing And, Provides Insights Into Regulatory Product Management Trends Across ... ... LONDON, July 17 The Scientific,business of Thomson Reuters today announced ... survey attracted respondents,from across the globe representing small, medium and large ...
Cached Biology Technology:Health Market Science Launches Clinical Investigators(TM) 2Health Market Science Launches Clinical Investigators(TM) 3Arno Therapeutics Announces New Ticker Symbol 2The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 2The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 3
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... N.M. A credit-card-sized anthrax detection cartridge developed at ... business makes testing safer, easier, faster and cheaper. ... anthrax, is commonly found in soils all over the ... in both humans and animals. The bacteria can survive ... B. anthracis may occur through skin contact, ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... of human embryonic,stem cells have been contaminated with ... in human subjects,according to research by investigators at ... Medicine and the Salk Institute in La Jolla,California.,In ... the journal Nature,Medicine, the researchers found that human ...
... Emory University School of,Medicine are conducting a clinical trial ... new blood vessels that could improve,circulation in patients with ... called peripheral vascular disease ,(PVD). Individuals with PVD ... especially during exercise, which causes pain, aching,cramping or fatigue ...
... that injecting iron into some major regions of the oceans ... something odd occurs as these tiny marine plants continue to ... acting as though iron, an essential nutrient, still is in ... could be that iron sets off a kind of chemical ...
Cached Biology News:Current human embryonic stem cell lines contaminated UCSD/Salk team finds 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 3Current human embryonic stem cell lines contaminated UCSD/Salk team finds 4Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs 2Growth in the sea comes down to a struggle for iron 2Growth in the sea comes down to a struggle for iron 3Growth in the sea comes down to a struggle for iron 4Growth in the sea comes down to a struggle for iron 5
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
ERalpha (Ser 104/106)...
... catalyzes the hydrolysis of 5-phosphate groups from ... This enzyme is used to prevent recircularization ... by removing phosphate groups from both 5-termini ... dephosphorylation of 5 phosphorylated ends of DNA ...
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Biology Products: